You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Minimally Invasive On Demand Electrical Nerve Block (OD-ENB) Device for Peripheral Pain
SBC: H-CUBED Topic: NIDAKnee Osteoarthritis (KOA) is a degenerative joint disease that leads to significant pain and functional disability affecting over 30% of older adults making it one of the most common and debilitating conditions related to aging. This disease results in a loss of mobility, reduced quality of life, and in ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Physics-informed Machine Learning approach for a selective, sensitive, and rapid sensor for detecting unsafe levels of carcinogenic/toxic VOCs
SBC: Prometheus Technologies, LLC Topic: NIEHSProject Summary Each year, between 340,000 and 900,000 premature deaths can be linked to air pollution caused by releasing Volatile Organic Compounds (VOCs), i.e., an estimated 1.8 billion tons of VOCs are emitted to the global environment each year. Also, some VOCs cause serious adverse health effects even at the trace level concentration, e.g., cancer, damage to the central nervous and immune sy ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Vitiligo topical treatment applying a potent, highly selective MC1R agonist
SBC: MC1R VENTURES LLC Topic: NIAMSPROJECT SUMMARY Vitiligo is the most common acquired hypopigmentary disorder that afflicts 0.5-2% of the world population, from all ethnicities and skin color. It is characterized by loss of melanocytes, which is often progressive, resulting in depigmented skin lesions. Vitiligo can be segmental (5-16% of all cases) or most commonly, non-segmental. It is a disease of young adults, as 25% of all no ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM)
SBC: NANOVALENT PHARMACEUTICALS INC Topic: 102Project Summary The goal of this Fast Track STTR project is to determine proof-of-principle and efficacy of a novel blood brain barrier (BBB) penetrating therapeutic nanoparticle for the potential treatment of otherwise intractable brain tumors like glioblastoma multiforme (GBM). This project seeks to demonstrate that novel, targetable nanoparticles can delivery therapeutic substances to human bra ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Microfluidic Technology for Concurrent Assessment of Red Blood Cell Adhesion and Deformability
SBC: BIOCHIP LABS, INC. Topic: NHLBIPROJECT SUMMARY Deformability and non-adherence are the most intrinsic biorheological properties of red blood cells (RBCs), as they play a critical role in modulating RBC perfusion through the microvasculature. In acquired or inherited blood disorders, such as sickle cell disease (SCD), these two interrelated properties are pathologically altered. SCD is an autosomal recessive disorder associated ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel Adipose Targeted Gene Therapy for Lipodystrophy
SBC: ZVELT THERAPEUTICS INC. Topic: NIDDKPROJECT SUMMARY Lipodystrophy includes a heterogeneous group of disorders that are characterized by abnormal or degenerative conditions of the adipose tissue. This rare and often underdiagnosed condition can be partial/localized or generalized and is generally associated with metabolic disorders such as insulin resistance, diabetes, hyperglycemia, hyperlipidemia, and other severe conditions. Lipod ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia
SBC: Haima Therapeutics LLC Topic: NHLBIProject Summary/Abstract The normal platelet count in human blood is 150,000-400,000/μL, and these platelets are responsible for efficient hemostatic surveillance and bleeding mitigation in the body. Thrombocytopenia (TCP, low platelet count) is a condition caused by a decrease in platelet production, increase in platelet destruction or consumption, or increase in splenic sequestration. The age-a ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Ceragenin-coated pedicle screws to tackle surgical-site infections.
SBC: N8 MEDICAL INC Topic: NIAIDPROJECT SUMMARY Surgical Site Infection (SSI) is one of the major complications of implant surgery, especially in spinal surgery, where SSI leads to unfavorable health and functional outcomes. Antimicrobial coatings have been explored as a way to prevent microbial colonization on the surface of pedicle screws. However, current strategies to generate antimicrobial coatings do not show broad-spectru ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes
SBC: IRXREMINDER LLC Topic: 104Abstract - Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes Tardive dyskinesia (TDD) is a common debilitating side effect of antipsychotic use. Characterized most notably by involuntary facial movements such as grimacing, involuntary lip, mouth, and tongue movements, and eye blinking, TDD is difficult to treat and potentially irreversible. Psychiatrists and othe ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Suicide, depression, and anxiety screening using an automated virtual assistant
SBC: CLARIGENT CORPORATION Topic: 104Summary: Each year in the US, more than 47,000 people die by suicide and many of these tragedies could be prevented with early identification and treatment. At-risk individuals rarely receive screening until depression, anxiety, and suicide symptoms are severe. Universal screening tools deployed in schools and physicians’ offices could address this problem, but the lack of an objective tool alon ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health